Relates to the latest 10-K of Merck & Co, for fiscal year ending December, 31 2019.

I need help answering the following using the table

• What amounts did Merck report for restructuring charges, in $ amounts and as percentage of sales?
• Describe briefly what kind of restructuring program relates to these charges?

Other Separation Accelerated Costs Depreciation Restructuring reserves January 1, 2018 $ 619 $ Expenses 473 (1) (Payments) receipts, net (649) Non-cash activity 1 Restructuring reserves December 31, 2018 443 Expenses 572 233 (Payments) receipts, net (325) Non-cash activity (233) Restructuring reserves December 31, 2019 $ 690 $ (1) The remaining cash outlays are expected to be substantially completed by the end of 2023. 128 $ 186 (238) 15 91 122 (136) (8) 69 $ Total 747 658 (887) 16 534 927 (461) (241) 759 (1) $ (b) Supplementary Data Selected quarterly financial data for 2019 and 2018 are contained in the Condensed Interim Financial Data table below. Condensed Interim Financial Data (Unaudited) (1) ($ in millions except per share amounts) 4th Q 3rd Q 2nd Q 1st Q 2019 (3) Sales Cost of sales Selling, general and administrative Research and development Restructuring costs Other (income) expense, net Income before taxes Net income attributable to Merck & Co., Inc. Basic earnings per common share attributable to Merck & Co., Inc. common shareholders Earnings per common share assuming dilution attributable to Merck & Co., Inc. common shareholders $ 11,868 $ 12,397 $ 11,760 $ 10,816 3,669 3,990 3,401 3,052 2,888 2,589 2,712 2,425 2,548 3,204 2,189 1,931 194 232 59 153 (223) 35 188 2,792 2,347 3,259 3,067 2,357 1,901 2,670 2,915 140 $ 0.93 $ 0.74 $ 1.04 $ 1.13 $ 0.92 $ 0.74 $ 1.03 $ 1.12 2018 (3) Sales $ 10,998 $ 10,794 $ 10,465 $ 10,037 Cost of sales 3,289 3,619 3,417 3,184 Selling, general and administrative 2,643 2,443 2,508 2,508 Research and development 2,214 2,068 2,274 3,196 Restructuring costs 138 171 228 95 Other (income) expense, net 110 (172) (48) (291) Income before taxes 2,604 2,665 2,086 1,345 Net income attributable to Merck & Co., Inc. 1,827 1,950 1,707 736 Basic earnings per common share attributable to Merck & Co., Inc. common shareholders $ 0.70 $ 0.73 $ 0.64 $ 0.27 Earnings per common share assuming dilution attributable to Merck & Co., Inc. common shareholders $ 0.69 0.73 $ 0.63 $ 0.27 Amounts for 2019 include a charge related to the acquisition of Peloton Therapeutics, Inc. (see Note 3). Amounts for 2018 include a charge related to the formation of a collaboration with Eisai (see Note 4). 3) Amounts for 2019 and 2018 reflect acquisition and divestiture-related costs (see Note 8) and the impact of restructuring actions (see Note 5). $ 927 The following table summarizes the charges related to restructuring program activities by type of cost: Separation Accelerated Costs Depreciation Other Total Year Ended December 31, 2019 Cost of sales $ 198 $ 53 $ 251 Selling, general and administrative 33 1 34 Research and development 2 2 4 Restructuring costs 572 66 638 S 572 233 $ 122 $ Year Ended December 31, 2018 Cost of sales S 10 $ 11 S 21 Selling, general and administrative 2 1 3 Research and development (13) 15 2 Restructuring costs 473 159 632 S 473 S (1) $ 186 S Year Ended December 31, 2017 Cost of sales S S 52 $ 86 S 138 Selling, general and administrative 2 2 Research and development 6 5 11 Restructuring costs 552 224 776 $ 552 $ 60 $ 315 $ 927 S 658 Other Separation Accelerated Costs Depreciation Restructuring reserves January 1, 2018 $ 619 $ Expenses 473 (1) (Payments) receipts, net (649) Non-cash activity 1 Restructuring reserves December 31, 2018 443 Expenses 572 233 (Payments) receipts, net (325) Non-cash activity (233) Restructuring reserves December 31, 2019 $ 690 $ (1) The remaining cash outlays are expected to be substantially completed by the end of 2023. 128 $ 186 (238) 15 91 122 (136) (8) 69 $ Total 747 658 (887) 16 534 927 (461) (241) 759 (1) $ Other Separation Accelerated Costs Depreciation Restructuring reserves January 1, 2018 $ 619 $ Expenses 473 (1) (Payments) receipts, net (649) Non-cash activity 1 Restructuring reserves December 31, 2018 443 Expenses 572 233 (Payments) receipts, net (325) Non-cash activity (233) Restructuring reserves December 31, 2019 $ 690 $ (1) The remaining cash outlays are expected to be substantially completed by the end of 2023. 128 $ 186 (238) 15 91 122 (136) (8) 69 $ Total 747 658 (887) 16 534 927 (461) (241) 759 (1) $ (b) Supplementary Data Selected quarterly financial data for 2019 and 2018 are contained in the Condensed Interim Financial Data table below. Condensed Interim Financial Data (Unaudited) (1) ($ in millions except per share amounts) 4th Q 3rd Q 2nd Q 1st Q 2019 (3) Sales Cost of sales Selling, general and administrative Research and development Restructuring costs Other (income) expense, net Income before taxes Net income attributable to Merck & Co., Inc. Basic earnings per common share attributable to Merck & Co., Inc. common shareholders Earnings per common share assuming dilution attributable to Merck & Co., Inc. common shareholders $ 11,868 $ 12,397 $ 11,760 $ 10,816 3,669 3,990 3,401 3,052 2,888 2,589 2,712 2,425 2,548 3,204 2,189 1,931 194 232 59 153 (223) 35 188 2,792 2,347 3,259 3,067 2,357 1,901 2,670 2,915 140 $ 0.93 $ 0.74 $ 1.04 $ 1.13 $ 0.92 $ 0.74 $ 1.03 $ 1.12 2018 (3) Sales $ 10,998 $ 10,794 $ 10,465 $ 10,037 Cost of sales 3,289 3,619 3,417 3,184 Selling, general and administrative 2,643 2,443 2,508 2,508 Research and development 2,214 2,068 2,274 3,196 Restructuring costs 138 171 228 95 Other (income) expense, net 110 (172) (48) (291) Income before taxes 2,604 2,665 2,086 1,345 Net income attributable to Merck & Co., Inc. 1,827 1,950 1,707 736 Basic earnings per common share attributable to Merck & Co., Inc. common shareholders $ 0.70 $ 0.73 $ 0.64 $ 0.27 Earnings per common share assuming dilution attributable to Merck & Co., Inc. common shareholders $ 0.69 0.73 $ 0.63 $ 0.27 Amounts for 2019 include a charge related to the acquisition of Peloton Therapeutics, Inc. (see Note 3). Amounts for 2018 include a charge related to the formation of a collaboration with Eisai (see Note 4). 3) Amounts for 2019 and 2018 reflect acquisition and divestiture-related costs (see Note 8) and the impact of restructuring actions (see Note 5). $ 927 The following table summarizes the charges related to restructuring program activities by type of cost: Separation Accelerated Costs Depreciation Other Total Year Ended December 31, 2019 Cost of sales $ 198 $ 53 $ 251 Selling, general and administrative 33 1 34 Research and development 2 2 4 Restructuring costs 572 66 638 S 572 233 $ 122 $ Year Ended December 31, 2018 Cost of sales S 10 $ 11 S 21 Selling, general and administrative 2 1 3 Research and development (13) 15 2 Restructuring costs 473 159 632 S 473 S (1) $ 186 S Year Ended December 31, 2017 Cost of sales S S 52 $ 86 S 138 Selling, general and administrative 2 2 Research and development 6 5 11 Restructuring costs 552 224 776 $ 552 $ 60 $ 315 $ 927 S 658 Other Separation Accelerated Costs Depreciation Restructuring reserves January 1, 2018 $ 619 $ Expenses 473 (1) (Payments) receipts, net (649) Non-cash activity 1 Restructuring reserves December 31, 2018 443 Expenses 572 233 (Payments) receipts, net (325) Non-cash activity (233) Restructuring reserves December 31, 2019 $ 690 $ (1) The remaining cash outlays are expected to be substantially completed by the end of 2023. 128 $ 186 (238) 15 91 122 (136) (8) 69 $ Total 747 658 (887) 16 534 927 (461) (241) 759 (1) $